Analysis of the distribution of veterinary antimicrobial products to veterinarians in Germany in 2011 and 2012.
For the implementation of risk management measures against the development and spread of antimicrobial resistances it is important to gain a quantitative insight into the use of veterinary antimicrobial agents. Since 2011, all pharmaceutical companies and wholesalers in Germany are required to report their sales data of veterinary antimicrobial products (VAPs). In 2011, 1706 t of antimicrobially active substances were sold to veterinarians registered in Germany, in 2012 the amount decreased to 1619 t. Tetracyclines and penicillins had the largest shares in both years, followed by sulfonamides, macrolides and polypeptides. Amoxicillin alone accounted for more than a quarter of the total amounts of all sold antimicrobials. In regard to AMR it is most important to limit the use of critically important antimicrobials, namely fluoroquinolones and 3rd and 4th generation cephalosporins. While in both years these groups accounted for less than 1% of the amount of sold antimicrobials, this does not reflect adequately their use, since they are used in much lower doses. Furthermore, it is worrying that the sales of fluoroquinolones and 3rd generation cephalosporins increased by 26% and 14%, respectively, between 2011 and 2012, while the sales of 4th generation cephalosporins decreased only by 2%. More than 95% of the active substances were contained in VAPs intended for oral application; only fluoroquinolones, 3rd and 4th generation cephalosporins as well as fenicols were primarily or even exclusively applied by injection.